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OBJECTIVES This study evaluated oxidative stress in the failing ventricle in patients with dilated
cardiomyopathy (DCM).
BACKGROUND Oxidative stress appears to increase in the failing myocardium and may contribute to
ventricular dysfunction in patients with DCM. Tumor necrosis factor-alpha (TNF-alpha),
which is expressed in the failing heart, may stimulate oxidative stress.
METHODS We measured plasma oxidized low density lipoprotein (oxLDL) by sandwich enzyme-linked
immunosorbent assay using specific antibodies against oxLDL in the aortic root (AO) and the
coronary sinus (CS) in control subjects (n 5 8) and in 22 patients with DCM and mild
congestive heart failure. We also measured the plasma levels of TNF-alpha and angiotensin
II.
RESULTS There was no difference in oxLDL between the AO and CS in control subjects. In contrast,
plasma oxLDL was significantly higher in the CS than the AO in patients with DCM,
suggesting that the transcardiac gradient of oxLDL reflects oxidative stress in the failing heart
in these patients. Plasma TNF-alpha levels were significantly higher in the CS than the AO
with a significant positive correlation of the transcardiac gradient of TNF-alpha and the
transcardiac gradient of oxLDL. Moreover, a significant negative correlation existed between
the transcardiac gradient of oxLDL and left ventricular ejection fraction. The transcardiac
gradient of plasma oxLDL was significantly lower in 6 patients who received carvedilol than
in 16 patients who did not receive carvedilol.
CONCLUSIONS These findings indicate that the transcardiac gradient of oxLDL may be a marker of oxidative
stress in the heart and that left ventricular dysfunction may be partly due to the oxidative stress
in patients with DCM. In addition, TNF-alpha may stimulate oxidative stress in the failing
heart in patients with DCM. (J Am Coll Cardiol 2001;37:2086–92) © 2001 by the
American College of Cardiology
Recent studies suggest that free radicals are increased in the
failing myocardium, and they may be important contribu-
tors to the deterioration of decompensating myocardium
(1–5). A chronic increase in myocardial oxidative stress is
capable of causing subcellular abnormalities, and this may
lead to cardiomyopathic changes and depressed contractile
function and failure (6–8). Thus, oxidative stress may be an
important susceptibility factor for dilated cardiomyopathy
(DCM) (9,10). Recently, plasma biochemical markers of
oxidative stress have been reported to be increased in
patients with congestive heart failure (CHF) including
DCM patients (5,11–13). However, there are no reports
showing the tissue origins of oxidative stress markers; both
poorly perfused peripheral muscles and the failing myocar-
dium may contribute to the increases.
Because free radicals cannot be measured directly in
humans, indirect markers of their activity have been used.
The most widely used index is the measurement of malon-
dialdehyde by the thiobarbituric acid-reacting substances
(TBARS) assay. However, there is a lack of specificity with
this assay (14). Recently, a sensitive and specific method of
measuring very low concentrations of oxidized low density
lipoprotein (oxLDL) was established (15,16). Therefore, in
the present study we tested the hypothesis that an elevated
transcardiac gradient of oxLDL resulting from oxidative
stress in the ventricle contributes to the pathophysiology of
DCM. A potentially important stimulus for increased oxi-
dative stress in the failing myocardium is exposure to
inflammatory cytokines, such as tumor necrosis factor-alpha
(TNF-alpha), which is expressed in the failing myocardium
(17–19) and has the ability to stimulate free radical produc-
tion (20–22). Another important stimulus that increases
free radicals is angiotensin II (Ang II) (23–26), which is
increased in plasma as well as in the hearts of patients with
DCM and CHF.
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The present study demonstrated that the transcardiac
gradient of oxLDL may be a marker of oxidative stress in
the heart and that left ventricular dysfunction may be partly
due to oxidative stress in patients with DCM (27). More-
over, the present study also indicated that TNF-alpha may
stimulate oxidative stress in patients with DCM and mild
CHF.
METHODS
Patients. The study population consisted of 22 consecutive
patients with mild CHF (left ventricular ejection fraction
[LVEF] ,45%) and DCM who were admitted to our
institution. The diagnosis of DCM was based on patient
history, physical examination, electrocardiogram, chest ra-
diography, echocardiography, left ventriculography and cor-
onary angiography. All patients were free of hypertension,
ischemic heart disease, valvular heart disease, congenital
malformations of the heart or vessels and intrinsic pulmo-
nary, renal or metabolic diseases. Endomyocardial biopsies
were obtained to rule out secondary cardiomyopathies
caused by viral or other infectious myocarditis, sarcoidosis,
amyloidosis or other metabolic heart disease. Patients with
secondary DCM were excluded from the study. Among the
22 patients with DCM, there were no patients with diabetes
mellitus or hyperlipidemia. We also selected eight age-
matched control subjects (aged 34 to 71 years, mean, 54 years)
with normal coronary arteries and no coronary spasm by
coronary angiography with intracoronary injection of ace-
tylcholine. Among the eight control subjects, there were no
patients with diabetes mellitus, hyperlipidemia or hyperten-
sion. Informed consent was obtained from all patients
before participating in the study, and the protocol was
approved by the Human Investigations Committee of our
institution.
The patients were 12 men and 10 women ranging in age
from 17 to 78 years (mean, 57 years). Five patients were
classified according to the standards of the New York Heart
Association (NYHA) as functional class I, and 17 patients
as functional class II. At entry into the study, 20 patients
were treated with furosemide, 15 with angiotensin-
converting enzyme inhibitors, 16 with digitalis and 6 with a
beta-blocker (carvedilol). Most drugs had been adminis-
tered for more than two months.
Study protocol. All patients were premedicated with an
oral dose of diazepam (5 mg), and they rested in bed in the
supine position for at least 20 min. Right-sided cardiac
catheterization was performed using a 7F Swan-Ganz
catheter. Blood samples for measuring plasma levels of
TBARS and oxLDL were collected simultaneously from
the aortic root (AO), coronary sinus (CS) and femoral vein.
Blood samples for measuring plasma levels of Ang II and
TNF-alpha were also collected from the AO and CS. A 6F
catheter (Goodman Co., Ltd, Nagoya, Japan) for blood
sampling was positioned in the CS, and the position of the
catheter was confirmed by injection of contrast medium just
after blood sampling. Left ventriculography was performed
using contrast medium after obtaining hemodynamic mea-
surements and blood samples.
Measurements of neurohumoral factors, thiobarbituric
acid reactive substances and oxLDL. Blood for measuring
plasma levels of TNF-alpha was transferred to a chilled tube
containing ethylenediaminetetraacetic acid (1 mg/ml) and
aprotinin (500 kallikrein inactivator U/ml), and then cen-
trifuged at 3,000 rpm for 15 min at 4°C. The plasma
obtained was stored at 230°C until assayed. The plasma
TNF-alpha level was determined using a commercially
available immunoassay (Quantikine HS, R&D Systems,
Minneapolis, Minnesota) as previously reported (28).
Plasma Ang II levels were measured using a radioimmuno-
assay with a specific antibody directed against synthetic Ang
II, as previously reported (29).
Blood for measuring plasma levels of the TBARS was
transferred to a plain tube, then centrifuged at 3000 rpm for
15 min at 4°C. The plasma obtained was stored at 230°C
until assayed. Lipid peroxide concentration was determined
by quantifying the TBARS as described previously (30).
Blood for measurement of the plasma levels of oxLDL was
transferred to a plain tube and centrifuged at 3,000 rpm for
15 min at 4°C; the plasma obtained was stored at 4°C until
it was assayed. Plasma oxLDL levels were measured using a
specific immunometric assay for human oxLDL using a kit
(Kyowa Medex, Co., Ltd, Tokyo, Japan) (16), which
employed a modification of a method previously reported
(15). Briefly, this assay system uses two antibodies against
human oxLDL, one recognizing a monoclonal antibody
against oxidized phosphatidylcholine (DLH3) (15) and the
other a polyclonal antibody against human apoprotein B,
respectively, and measures oxLDL by sandwiching it be-
tween the two antibodies.
Before the assay, the plasma sample was diluted 1/250
with a dilution buffer, and the DLH3-coated plates were
washed three times with a phosphate-buffered saline and
patted dry. A dilution buffer (100 ml) was added to each well
of the plates, and 20 ml of the diluted sample or calibrator
was added and mixed with the dilution buffer in the plates.
Next, plates were incubated for 2 h at 37°C. After plates
were washed five times with washing buffer, horseradish
peroxidase-labeled antiapoprotein B-100 goat IgG was
added to each well, and the plates were incubated for 1 h at
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37°C. After the plates were washed five times with washing
buffer, 100 ml of 3,39,5,59-tetramethylbenzidine solution
was added to each well, and the plates were then incubated
for 30 min at 37°C. To stop the enzyme reaction, 100 ml of
1 mol/liter sulphuric acid was added, and the absorbance at
450 nm was measured with a MTP-120 plate reader
(Corona Electric, Ibaragi, Japan).
Statistical analysis. All results are expressed as the mean 6
SEM. Univariate analyses were performed using the Stu-
dent t test. Comparisons between multiple groups were
determined by one-way analysis of variance using the
Scheffe´ F test. Categoric data were compared against a
chi-square distribution. Univariate and stepwise multivari-
ate linear regression analyses were used to detect indepen-
dent predictors of the transcardiac gradient of plasma
oxLDL among the 11 variables. Linear regression analysis
was used to determine the relationship between continuous
variables. A p value , 0.05 was regarded as significant.
RESULTS
Clinical characteristics and hemodynamic data. There
was no difference in age, gender or plasma levels of total
cholesterol, LDL cholesterol, high density lipoprotein cho-
lesterol or triglycerides between the control subjects and
patients with DCM. The mean LVEF of the patients with
DCM was 31%, and LVEF was significantly lower in
patients with DCM than in control subjects (Table 1).
Comparison of plasma concentrations of TBARS and
oxLDL in the AO and CS. There was no difference in
plasma levels in TBARS between the AO and the CS in 8
control subjects (2.8 6 0.2 vs. 2.5 6 0.2 nmol/ml) and in 22
patients with DCM (2.2 6 0.1 vs. 2.1 6 0.1 nmol/ml). In
the 8 control subjects, no difference existed in the oxLDL
level between the AO and CS (Fig. 1) (9.4 6 0.8 vs. 10.1 6
1.0 U/ml); in the 22 patients with DCM, the plasma
oxLDL level was significantly higher in the CS than in the
AO (Fig. 1) (28.6 6 3.4 vs. 16.4 6 2.0 U/ml, p , 0.01). No
difference existed between the oxLDL level in the AO and
in the femoral vein in control subjects or in patients with
DCM. The plasma levels of oxLDL in the AO, CS and
femoral vein were significantly higher in patients with
DCM than in control subjects (Fig. 1).
Relationship between the transcardiac gradient of plasma
oxLDL and left ventricular function. Figure 2 shows a
significant negative correlation between the transcardiac
gradient of plasma oxLDL [(CS 2 AO) oxLDL] and LVEF.
A significant negative correlation existed between the trans-
cardiac gradient of plasma oxLDL [(CS 2 AO) oxLDL]
and LVEF in 30 subjects, consisting of both patients with
DCM and the control subjects (r 5 20.565, p 5 0.0011),
and in 22 patients with DCM (r 5 20.455, p , 0.05). A
significant positive correlation existed between the transcar-
diac gradient of plasma oxLDL [(CS 2 AO) oxLDL] and
left ventricular end-diastolic volume index in the 30 subjects
consisting of the patients with DCM plus control subjects
(r 5 0.405, p 5 0.023) (Fig. 3).
Comparison of plasma levels of oxLDL and neurohu-
moral factors in patients who received carvedilol and
patients who did not receive carvedilol. In the present
study, six patients received carvedilol (mean doses,
15 mg/day), which has an antioxidant effect. There was no
difference in hemodynamic parameters and other treatments
between the two groups (Table 2). There was also no
significant difference in the plasma level of oxLDL in the
AO or the plasma levels of TNF-alpha or Ang II in the AO
and CS between the two groups, but the transcardiac
gradient of plasma oxLDL was significantly lower in the 6
patients who received carvedilol than in the 16 patients who
did not receive carvedilol (Fig. 4). The transcardiac gradient
of plasma TNF-alpha was also significantly lower in the 6
patients who received carvedilol than in the 16 patients who
did not receive carvedilol.
Figure 1. Plasma oxidized low density lipoprotein (oxLDL) concentrations
in the aortic root (AO), coronary sinus (CS) and femoral vein (FV) in 8
control subjects and in 22 patients with dilated cardiomyopathy. Open
columns represent control subjects; closed columns represent patients
with dilated cardiomyopathy. *p , 0.05; **p , 0.01 between the value of
normal subjects and patients with dilated cardiomyopathy; #p , 0.01 vs.
the value of AO by analysis of variance with the Scheffe´ F test.
Table 1. Clinical Characteristics and Hemodynamic Data
Age
(y)
Gender
(M/F)
TC
(mg/dl)
LDL-C
(mg/dl)
HDL-C
(mg/dl)
TG
(mg/dl)
LVEF
(%)
MBP
(mm Hg)
RA
(mm Hg)
PCWP
(mm Hg)
LVEDP
(mm Hg)
LVEDVI
(l/min/m2)
Control (n 5 8) 54 5/3 185 115 40.7 107 67 98.6 2.3 5.5 7.6 79
(SE) (4.5) — (10) (6.7) (3.4) (19) (2.3) (5.8) (1.1) (0.6) (0.5) (3.8)
DCM (n 5 22) 57 12/10 181 108 46.7 109 31** 82.5* 2.5 8.7 13.1* 168**
(SE) (4.0) — (7.2) (7.4) (2.5) (10) (1.9) (3.1) (0.3) (1.0) (1.3) (12)
*p , 0.05. **p , 0.0001 vs. control (control subjects).
DCM 5 dilated cardiomyopathy; HDL-C 5 high density lipoprotein cholesterol; LDL-C 5 low density lipoprotein cholesterol; LVEDP 5 left ventricular end-diastolic
pressure; LVEDVI 5 left ventricular end-diastolic volume index; LVEF 5 left ventricular ejection fraction; MBP 5 mean arterial blood pressure; PCWP 5 pulmonary capillary
wedge pressure; RA 5 right atrial pressure; SE 5 standard error; TC 5 total cholesterol; TG 5 triglycerides.
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Relationship between the transcardiac gradient of plasma
TNF-alpha and the transcardiac gradient of plasma
oxLDL in patients with DCM. There was no difference in
the plasma level of Ang II between the AO and the CS, but
plasma levels of TNF-alpha were significantly higher in the
CS than those in the AO. No correlation was seen between
the plasma levels of TNF-alpha in the AO and CS and the
transcardiac gradient of oxLDL, but a significant correlation
existed between the transcardiac gradient of plasma TNF-
alpha and the transcardiac gradient of plasma oxLDL in 22
patients with DCM (Fig. 5). Table 3 shows the results of
univariate and multivariate analyses among 11 variables to
assess the factors regulating the transcardiac gradient of
plasma oxLDL. According to stepwise multivariate analy-
ses, only the transcardiac gradient of plasma TNF-alpha was
a significant independent predictor of the transcardiac
increase in plasma oxLDL in 22 patients with DCM and
mild CHF.
DISCUSSION
Plasma oxLDL as a sensitive marker of oxidative sress in
patients with DCM. Recently, increases in plasma bio-
chemical markers of oxidative stress have been reported in
patients with CHF, including patients with DCM (5,11–
13). However, there is no report showing the tissue origins
of oxidative stress markers except for one report in which
pericardial fluid samples were analyzed (31). Thus, it re-
Figure 2. Correlation between the transcardiac gradient of plasma oxidized
low density lipoprotein (oxLDL) and left ventricular ejection fraction
(LVEF). AO 5 aortic root; CS 5 coronary sinus; open triangles represent
control subjects; open circles represent patients with dilated cardiomyop-
athy.
Figure 3. Correlation between the transcardiac gradient of plasma oxidized
low density lipoprotein (oxLDL) and left ventricular end-diastolic volume
index (LVEDVI). AO 5 aortic root; CS 5 coronary sinus; open triangles
represent control subjects; open circles represent patients with dilated
cardiomyopathy.
Table 2. Characteristics of 22 Patients with CHF Divided Into
Two Groups: Carvedilol Treatment or No Carvedilol Treatment
Carvedilol (2)
(n 5 16)
Carvedilol (1)
(n 5 6)
p
Value
Age (yr) 56.2 6 5.3 59.3 6 5.4 NS
Gender (M/F) 10/6 2/4 NS
NYHA functional class
I 3 2 NS
II 13 4 NS
HR (beats/min) 81 6 5 64.2 6 4.6 0.063
MBP (mm Hg) 82.5 6 3.3 82.1 6 7.6 NS
CI (liter/min/m2) 2.7 6 0.2 2.4 6 0.2 NS
LVEDP (mm Hg) 12.9 6 1.4 13.8 6 3.0 NS
LVEF (%) 29.8 6 2.1 33.7 6 3.2 NS
Ang II in AO (pg/ml) 17 6 4.1 52 6 39 NS
Ang II in CS (pg/ml) 21 6 6.4 43 6 28 NS
TNF-alpha in AO (pg/ml) 3.5 6 0.5 4.5 6 1.3 NS
TNF-alpha in CS (pg/ml) 4.6 6 0.5 4.5 6 1.0 NS
(CS-AO) TNF-alpha (pg/ml) 1.1 6 0.2 20.03 6 0.3 0.008
oxLDL in AO (U/ml) 14.9 6 2.3 20.7 6 4.5 NS
oxLDL in CS (U/ml) 30.9 6 4.4 22.3 6 3.5 NS
(CS-AO) oxLDL (U/ml) 16.1 6 3.2 1.7 6 1.3 0.015
Treatment
Furosemides 14 6 NS
Digitalis 10 6 NS
ACE inhibitors 10 5 NS
ACE 5 angiotensin-converting enzyme; Ang II 5 angiotensin II; AO 5 aortic root;
CI 5 cardiac index; CS 5 coronary sinus; HR 5 heart rate; LVEDP 5 left
ventricular end-diastolic pressure; LVEF 5 left ventricular ejection fraction; MBP 5
mean arterial blood pressure; oxLDL 5 oxidized low density lipoprotein; TNF-
alpha 5 tumor necrosis factor-alpha.
Figure 4. Comparison of the transcardiac gradient of oxidized low density
lipoprotein (oxLDL) between 6 patients who received carvedilol and 16
patients who did not receive carvedilol. AO 5 aortic root; CS 5 coronary
sinus. *p , 0.05 vs. carvedilol (2).
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mains possible that these markers arise from poorly perfused
peripheral muscles and/or the failing myocardium. Our
findings indicated that there was no difference in plasma
oxLDL between the AO and the femoral vein, but the
plasma oxLDL level was significantly higher in the CS than
in the AO, suggesting that the source of the increase in
plasma oxLDL, a marker of oxidative stress, is of myocardial
origin rather than peripheral origin in patients with DCM
and mild CHF.
Because the evaluation of oxidative stress in the heart is
difficult in vivo, we measured the transcardiac oxLDL
gradient as a marker of oxidative stress in the heart. We also
measured plasma TBARS, but there was no difference
between the AO and the CS. In the present study, there was
a significant increase in plasma oxLDL from the AO to the
CS in patients with DCM, suggesting: 1) plasma oxLDL is
a sensitive maker of oxidative stress, and 2) that there is an
increase in the production of free radicals such as superoxide
radical and/or a decrease in free radical scavengers in the
failing hearts of patients with DCM. Moreover, the in-
creased transcardiac gradient of plasma oxLDL was nega-
tively correlated with LVEF. Our findings are consistent
with those of experimental studies in which free radicals
depressed myocardial contractile function (6–8).
TNF-alpha as a potential stimulator of oxidative stress in
patients with DCM. A potentially important stimulus for
increased oxidative stress in the myocardium is exposure to
inflammatory cytokines, such as TNF-alpha which is ex-
pressed in the failing myocardium but not in the healthy
heart (17–19) and which has the ability to stimulate free
radical production (10–22). The other important stimulus
for increased free radicals is Ang II (23–26), which is
increased in plasma as well as in the hearts of patients with
DCM and CHF, and which has the ability to stimulate free
radical production.
In the present study, a transcardiac increase in TNF-
alpha was observed in patients with DCM and mild CHF,
suggesting that TNF-alpha is produced in myocardial tissue
and the source of increased plasma TNF-alpha is partly the
failing heart. Although no correlation was seen between the
plasma levels of TNF-alpha in the AO and CS and the
transcardiac gradient of oxLDL, the transcardiac gradient of
TNF-alpha significantly correlated with the transcardiac
gradient of oxLDL, indicating that the local production of
TNF-alpha in the heart stimulates oxidative stress in the
failing heart with DCM. Previous studies reported that
myocardial overexpression of TNF-alpha causes ventricular
dilation, ventricular dysfunction and interstitial fibrosis like
DCM (32,33), suggesting the local expression of TNF-
alpha in the heart plays a causal role in the pathogenesis of
DCM. Taken together with the present study, oxidative stress
induced by the local production of TNF-alpha in the heart
may cause left ventricular dysfunction in patients with DCM.
In the present study, there was no difference in the plasma
level of Ang II between the AO and the CS there was no
relation between plasma levels of Ang II in the AO, CS and
the transcardiac gradient of Ang II and the transcardiac
gradient of oxLDL. In contrast to TNF-alpha, Ang II is not
only produced but also extracted through the heart (34), so
it is difficult to evaluate the tissue level of Ang II in the
Figure 5. Correlation between the transcardiac gradient of plasma tumor
necrosis factor-alpha (TNF-alpha) and the transcardiac gradient of plasma
oxidized low density lipoprotein (oxLDL) in patients with dilated cardio-
myopathy. AO 5 aortic root; CS 5 coronary sinus.
Table 3. Univariate and Multivariate Linear Model of Transcardiac Gradient of oxLDL in 22
Patients With DCM
Variable
Univariate Correlation
Coefficient
p
Value
Multivariate
Beta-Coefficient (SE)
p
Value
NYHA functional class 20.033 NS
Age (yr) 20.039 NS
LVEF (%) 24.55 0.0332
Ang II in AO (pg/ml) 20.138 NS
Ang II in CS (pg/ml) 20.97 NS
(CS-AO) Ang II (pg/ml) 0.172 NS
TNF-alpha in AO (pg/ml) 20.125 NS
TNF-alpha in CS (pg/ml) 20.086 NS
(CS-AO) TNF-alpha (pg/ml) 0.544 0.0088 8.4 (2.89) 0.0088
Treatment (treatment 5 1)
ACE inhibitors 20.123 NS
Carvedilol 20.509 0.0156
ACE 5 angiotensin-converting enzyme; Ang II 5 angiotensin II; AO 5 aortic root; CS 5 coronary sinus; LVEF 5 left
ventricular ejection fraction; NYHA 5 New York Heart Association; TNF-alpha 5 tumor necrosis factor-alpha.
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failing heart. Therefore, we cannot deny the potential role
of local Ang II as a stimulator of oxidative stress in the
failing heart with DCM.
Clinical implications. Several studies have provided strong
evidence that enhanced lipid peroxidation and oxygen free
radical damage persists in patents with CHF (1–8). Al-
though the precise cellular sources of oxygen free radicals
and the mechanisms involved in initiating the oxidative
stress that occurs in patients with CHF remain unknown,
our findings suggest that failing myocardium is one of the
sources of the increase in free radicals in patients with
DCM. It is conceivable that oxygen free radicals produced
by the myocardium contribute to myocardial cellular toxicity
and damage and to apoptosis (1,2). It has been proposed
that the link among oxygen free radical formation, cardiac
remodeling and apoptosis involves the activation of specific
transcription factors in cardiac myocytes. In this respect,
antioxidants have been proposed to attenuate the oxygen
free radical–derived transcriptional events that are respon-
sible for cardiac remodeling and apoptosis. In the present
study, there was a significant positive correlation between
the transcardiac gradient of plasma oxLDL and left ventric-
ular end-diastolic volume index. Six patients received carve-
dilol, which has an antioxidant effect, and the transcardiac
gradients of plasma oxLDL and TNF-alpha were signifi-
cantly lower in patients receiving carvedilol therapy than in
patients not receiving carvedilol, suggesting that carvedilol
may reduce the oxidative stress of the failing heart of DCM
patients. However, we cannot deny the possibility that
carvedilol reduced the transcardiac gradient of oxLDL
through its beta-blocking, metabolic and remodeling effects
as opposed to its antioxidant properties. Therefore, the
effects of antioxidant drugs, including other beta-blockers
such as metoprolol on the serial changes in the transcardiac
gradient of oxLDL need to be studied.
Study limitations. In the present study, we evaluated
patients with DCM and mild CHF. In patients with severe
CHF, Ang II and TNF-alpha, which are more activated in
the failing heart than in mild CHF patients, may stimulate
oxidative stress and exacerbate the transcardiac gradient of
oxLDL. Further studies are needed to evaluate the relation-
ship between the severity and/or etiology of CHF and the
transcardiac gradient of oxLDL.
Conclusions. In conclusion, this is the first study, to our
knowledge, to demonstrate that the transcardiac gradient of
oxLDL may be a marker of oxidative stress in the heart and
that left ventricular dysfunction may be partly due to
oxidative stress in patients with DCM. Moreover, the
present study indicated that TNF-alpha may stimulate
oxidative stress in the failing heart in patients with DCM.
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